Your search for rivaroxaban returned 154 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Your search for rivaroxaban returned 154 results

Sort Results:

Relevant Recent

Janssen has announced results from its Phase 3b exploratory trial evaluating the efficacy of Xarelto (rivaroxaban) as an alternative to vitamin K antagonists (VKAs) for treating and reducing the risk of blood clots in non-valvular atrial fibrillation (NVAF) in patients undergoing elective cardioversion.

A new pooled analysis of the Phase 3 EINSTEIN trial program showed that Xarelto had similar efficacy as the standard of care in reducing the risk of DVT and PE in patients with symptomatic DVT/PE.

Results of a study conducted by Janssen show that prothrombin complex concentrates can reverse the blood thinning effects of Xarelto (rivaroxaban) in healthy subjects.